Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial
Status:
Completed
Trial end date:
2020-07-20
Target enrollment:
Participant gender:
Summary
Despite all prevention efforts, many people in Australia continue to be infected with HIV.
The Seventh National HIV Strategy 2014-2017 in Australia aims to work towards the elimination
of HIV transmission by the year 2020. This project will evaluate a new additional way to
lower people's chances of getting HIV. It will provide pre-exposure prophylaxis (PrEP) to
people who are at high risk for HIV and evaluate what impact this new prevention approach
will have on HIV in WA at the community level.
The drug used in PREPIT-WA is called generic TDF/FTC (made by Mylan Laboratories Ltd.). The
generic TDF/FTC is a single tablet made up of two HIV medications: tenofovir disoproxil
fumarate and emtricitabine (a combination known as TDF/FTC). TDF and FTC have been widely
used for many years to treat HIV. When used with other medicines in people who already have
HIV, TDF/FTC reduces the amount of HIV virus in the blood. TDF/FTC does not cure HIV or AIDS,
and it is not an HIV vaccine.
As a treatment for people who already have HIV, TDF/FTC is approved for use in most of the
world, including Australia. As a medicine for PrEP, to lower chances of HIV in those who are
not infected, TDF/FTC has been approved in the US, and Truvada® (which contains TDF/FTC made
by Gilead Sciences Inc.) was approved for PrEP in Australia in May 2016. At the start of the
project, the generic TDF/FTC is not approved in Australia for the use as PrEP but it may
become registered for use and more freely available in Australia in the future.
Phase:
Phase 3
Details
Lead Sponsor:
Kirby Institute
Collaborators:
Government of Western Australia, Department of Health Western Australia AIDS Council